OJSC Biosintez
| Date | Investors | Amount | Round |
|---|---|---|---|
$24.0m Valuation: $24.0m 0.5x EV/Revenue | Acquisition | ||
| Total Funding | 000k | ||
| EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 13 % | (17 %) | (31 %) | 33 % | 2 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | 29 % | 6 % | 18 % | 26 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (1 %) | - | (22 %) | (1 %) | 8 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
OJSC Biosintez, a prominent player in the pharmaceutical industry, has a rich history that reflects its commitment to innovation and growth. Founded in 1955 in Penza, Russia, the company was established to address the growing need for high-quality pharmaceutical products in the region. Over the years, Biosintez has evolved from a local manufacturer to a significant entity in the pharmaceutical sector, known for its production of a wide range of medicinal products.
Throughout its journey, Biosintez has focused on expanding its product line and enhancing its manufacturing capabilities. This strategic focus has enabled the company to meet the increasing demands of both domestic and international markets. The company's dedication to quality and innovation has been a driving force behind its success.
A significant milestone in Biosintez's history was its acquisition by Sun Pharmaceutical Industries Ltd., one of the world's largest specialty generic pharmaceutical companies. This acquisition, completed in 2016, marked a new chapter for Biosintez, providing it with the resources and expertise to further expand its operations and product offerings.
Today, OJSC Biosintez continues to thrive as a key player in the pharmaceutical industry, leveraging its rich history and the support of Sun Pharmaceutical to deliver innovative healthcare solutions. The company's journey is a testament to its resilience and adaptability in an ever-evolving industry.